English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/217310
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorEspadas, I.-
dc.contributor.authorKeifman E-
dc.contributor.authorPalomo-Garo, Cristina-
dc.contributor.authorBurgaz, S.-
dc.contributor.authorGarcía, C.-
dc.contributor.authorFernández-Ruiz, Javier-
dc.contributor.authorMoratalla, Rosario-
dc.date.accessioned2020-08-03T11:10:02Z-
dc.date.available2020-08-03T11:10:02Z-
dc.date.issued2020-
dc.identifierdoi: 10.1016/j.nbd.2020.104892-
dc.identifierissn: 1095-953X-
dc.identifier.citationNeurobiology of Disease 141 (2020)-
dc.identifier.urihttp://hdl.handle.net/10261/217310-
dc.description.abstractThe antioxidant and CB receptor agonist properties of Δ-tetrahydrocannabivarin (Δ-THCV) afforded neuroprotection in experimental Parkinson's disease (PD), whereas its CB receptor antagonist profile at doses lower than 5 mg/kg caused anti-hypokinetic effects. In the present study, we investigated the anti-dyskinetic potential of Δ-THCV (administered i.p. at 2 mg/kg for two weeks), which had not been investigated before. This objective was investigated after inducing dyskinesia by repeated administration of L-DOPA (i.p. at 10 mg/kg) in a genetic model of dopaminergic deficiency, Pitx3 mutant mice, which serves as a useful model for testing anti-dyskinetic agents. The daily treatment of these mice with L-DOPA for two weeks progressively increased the time spent in abnormal involuntary movements (AIMs) and elevated their horizontal and vertical activities (as measured in a computer-aided actimeter), signs that reflected the dyskinetic state of these mice. Interestingly, when combined with L-DOPA from the first injection, Δ-THCV delayed the appearance of all these signs and decreased their intensity, with a reduction in the levels of FosB protein and the histone pAcH3 (measured by immunohistochemistry), which had previously been found to be elevated in the basal ganglia in L-DOPA-induced dyskinesia. In addition to the anti-dyskinetic effects of Δ-THCV when administered at the onset of L-DOPA treatment, Δ-THCV was also effective in attenuating the intensity of dyskinesia when administered for three consecutive days once these signs were already present (two weeks after the onset of L-DOPA treatment). In summary, our data support the anti-dyskinetic potential of Δ-THCV, both to delay the occurrence and to attenuate the magnitude of dyskinetic signs. Although further studies are clearly required to determine the clinical significance of these data in humans, the results nevertheless situate Δ-THCV in a promising position for developing a cannabinoid-based therapy for patients with PD.-
dc.description.sponsorshipThis work was supported by grants from CIBERNED (CB06/05/0055 (RM), PI2018/01-3 (JF-R) and CB06/05/0089 (JF-R)), MINEICO (SAF2016-78207-R and PCIN-2015-098 (RM), and SAF2015-68580-C2-1-R to JF-R), Instituto de Salud Carlos III (PNSD2016I033) (RM), the Ramón Areces Foundation (172275) (RM), and GW Research Ltd., UK (JF-R). Funding was also provided by the EMHE “Enhancing Mobility between Latin American and Caribbean countries and Europe”- a CSIC program, to Ettel Keifman. Sonia Burgaz is a predoctoral fellow supported by the Complutense University-Predoctoral Programme. These agencies had no further role in study design, collection, analysis and interpretation of the data, in the writing of the report, or in the decision to submit the paper for publication.-
dc.languageeng-
dc.publisherAcademic Press-
dc.relationMINECO/ICTI2013-2016/SAF2016-78207-R-
dc.relationMINECO/ICTI2013-2016/PCIN-2015-098-
dc.relationMINECO/ICTI2013-2016/SAF2015-68580-C2-1-R-
dc.relation.isversionofPublisher's version-
dc.rightsopenAccess-
dc.subjectParkinson's disease-
dc.subjectL-DOPAL-DOPA-induced dyskinesia-
dc.subjectCannabinoids-
dc.subjectΔ9-THCV-
dc.subjectCB1 receptors-
dc.subjectCB2 receptors-
dc.titleBeneficial effects of the phytocannabinoid Δ9-THCV in L-DOPA-induced dyskinesia in Parkinson's disease-
dc.typeartículo-
dc.identifier.doihttp://dx.doi.org/10.1016/j.nbd.2020.104892-
dc.relation.publisherversionhttp://dx.doi.org/10.1016/j.nbd.2020.104892-
dc.date.updated2020-08-03T11:10:03Z-
dc.rights.licensehttps://creativecommons.org/licenses/by-nc-nd/4.0/-
dc.contributor.funderCentro Investigación Biomédica en Red Enfermedades Neurodegenerativas (España)-
dc.contributor.funderMinisterio de Economía y Competitividad (España)-
dc.contributor.funderInstituto de Salud Carlos III-
dc.contributor.funderFundación Ramón Areces-
dc.relation.csic-
dc.identifier.funderhttp://dx.doi.org/10.13039/100008054es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100004587es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100003329es_ES
Appears in Collections:(IC) Artículos
Files in This Item:
File Description SizeFormat 
Beneficial effects of the.pdf1,1 MBAdobe PDFThumbnail
View/Open
Show simple item record
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.